Market Overview

UPDATE: Stifel Nicolaus Initiates Abbott Laboratories at Buy Post Spin

Share:
Related ABT
BMO On Abbott Labs: 'It's Likely Time For The Stock To Take A Pause'
Benzinga's Top Upgrades, Downgrades For March 14, 2017
Pharma Development Budgets Grow As Roche Remains A Believer (Seeking Alpha)

Stifel Nicolaus initiated Abbott Laboratories (NYSE: ABT) with a Buy rating and a $40.00 price target.

Stifel Nicolaus commented, "Post-spin, we believe Abbott is now a balanced, diversified medical products company with an attractive, long-term outlook for mid-to-upper single-digit sales growth and low double-digit EPS growth. Although ABT currently trades at a premium to its peers, we see potential for further EPS upside over time, driven by an intensified focus on growth and margin enhancing initiatives. Using a sum-of-the-parts valuation framework, we arrive at a $40 target price."

Abbott Laboratories closed at $34.46 on Thursday.

Latest Ratings for ABT

DateFirmActionFromTo
Mar 2017BMO CapitalDowngradesOutperformMarket Perform
Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!